文献速递系统性红斑狼疮其他结缔组织病

氨来呫诺抑制I型干扰素产生并抑制B细胞分化:系统性红斑狼疮及其他系统性炎症疾病的潜在治疗选择

Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases.
PubMed 文献 · RMD Open · 2025-05-07

研究评估TBK1抑制剂氨来呫诺对外周血单个核细胞I型干扰素产生及B细胞分化的影响。氨来呫诺抑制内体和胞质途径诱导的I型干扰素产生,并抑制B细胞增殖、分化为浆母细胞和浆细胞及IgM和IgG产生,在SLE、pSjD和SSc患者B细胞中亦得到验证。

要点

  • 氨来呫诺抑制内体和胞质途径诱导的I型干扰素产生。
  • 氨来呫诺抑制B细胞增殖、分化为CD27highCD38highCD138+/-浆母细胞和浆细胞及IgM和IgG产生。
  • 在SLE、pSjD和SSc患者B细胞中验证了上述抑制效应。

核心结论

  • 氨来呫诺在原代人细胞中抑制I型干扰素产生和B细胞分化,抑制TBK1可能成为I型干扰素驱动的系统性炎症疾病的潜在治疗选择。

研究设计与样本

  • 研究评估氨来呫诺对经Imiquimod、CpG-A、Poly:IC、G3-YsD和3p-hpRNA刺激的外周血单个核细胞的作用。
  • 将健康对照及SLE、pSjD和SSc患者的B细胞与CD40L、IL-21、IFN、B细胞激活因子(BAFF)及氨来呫诺共培养。

主要发现

  • 氨来呫诺抑制外周血单个核细胞中经内体和胞质途径诱导的I型干扰素产生。
  • 氨来呫诺处理细胞的上清液不诱导BAFF和MX1表达。
  • 氨来呫诺抑制SLE、pSjD和SSc患者外周血单个核细胞中自发性MX1表达。
  • 免疫组化染色证实pSjD唾液腺中TBK1蛋白表达。
  • 氨来呫诺减少B细胞增殖和分化为CD27highCD38highCD138+/-浆母细胞和浆细胞,并抑制IgM和IgG产生,在SLE、pSjD和SSc患者B细胞中得到验证。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Activation of the type I interferon (IFN) pathway and autoreactive B cells are key immunopathogenic features of systemic lupus erythematosus (SLE), primary Sjögren's disease (pSjD) and systemic sclerosis (SSc). TANK-binding kinase 1 (TBK1) is a mediator of type I IFN and essential during B cell development in mice. We investigated the properties of the TBK1 inhibitor amlexanox in systemic autoimmune diseases. METHODS: The effects of amlexanox on peripheral blood mononuclear cells (PBMCs) stimulated with Imiquimod, CpG-A, Poly:IC, G3-YsD and 3p-hpRNA were assessed. B cells from healthy controls and patients with SLE, pSjD and SSc were cultured with CD40L, IL-21, IFN, B cell activating factor (BAFF) and amlexanox. Differentiation into CD38highCD27highCD138+/- cells, proliferation, and IgM and IgG production were measured. RESULTS: Amlexanox inhibited production of type I IFN induced through endosomal and cytosolic routes in PBMCs. Likewise, supernatants from amlexanox-treated cells did not induce expression of BAFF and MX1. Amlexanox inhibited spontaneous MX1 expression in PBMCs from SLE, pSjD and SSc patients. Immunohistochemical staining confirmed expression of the TBK1 protein in pSjD salivary glands. Using a B cell differentiation assay, addition of amlexanox decreased B cell proliferation and differentiation into CD27highCD38highCD138+/- plasmablasts and plasma cells. Correspondingly, production of IgM and IgG was suppressed. The observations were corroborated in B cells from patients with SLE, pSjD and SSc. CONCLUSIONS: Our findings demonstrate inhibitory effects of amlexanox on type I IFN production and B cell differentiation in primary human cells. Inhibition of TBK1 could potentially be a therapeutic option for the treatment of type I IFN-driven systemic inflammatory diseases.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Björk A, Wahadat MJ, Sánchez-Blázquez M, et al. Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases. RMD Open. 2025. PMID: 40341181. doi:10.1136/rmdopen-2024-005351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。